Our anti-SIRPα antibodies alone did not augment macrophage phagocytic activity, a finding consistent with results from other groups demonstrating that anti-SIRPα antibody (BMS-986351) treatment alone exhibits limited efficacy [8], which may be attributed to the suboptimal interaction between SIRPα on macrophages and CD47 expressed on the colorectal tumor cells used in our study. The gene discussed is CD47; the disease is colorectal neoplasm.